# RICE-ibrutinib in Relapsed DLBCL

> **NCT02955628** · PHASE2 · UNKNOWN · sponsor: **Singapore General Hospital** · enrollment: 34 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Diffuse Large B-Cell Lymphoma Recurrent

## Interventions

- **DRUG:** Ibrutinib-RICE

## Key facts

- **NCT ID:** NCT02955628
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12-13
- **Primary completion:** 2023-08
- **Final completion:** 2023-08
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2017-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02955628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02955628, "RICE-ibrutinib in Relapsed DLBCL". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02955628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*